Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resatorvid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 known ✓ | O00206 | 9/20 | 1.00 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resatorvid SCHEMBL29607069 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL871572 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL1821271 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL30113148 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871253 | 0.97 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871685 | 0.94 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944442 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944682 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944518 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944446 | 0.90 | TLR4 (0.85) | TLR4MRGPRX1TSPOHRH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594278-B2 | Method for treatment of muscular dystrophy | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2026-04-07 | — | — | US | claimed |
| US-20260034087-A1 | COMPOSITION COMPRISING A TLR4/MD2 PATHWAY INHIBITOR AND AN EGFR INHIBITOR AND ITS USE IN CANCER TREATMENT | UNIV HONG KONG BAPTIST UNIV (CN) | 2026-02-05 | — | — | US | claimed |
| US-20250375534-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | BioNTech SE (DE) | 2025-12-11 | — | — | US | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2025-08-21 | — | — | US | claimed |
| EP-4585223-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-20250177503-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-06-05 | — | — | US | claimed |
| EP-4110368-B1 | TREATMENT OF LIVER FAILURE | HEPYX LTD (GB) | 2025-06-04 | — | — | EP | claimed |
| US-11400059-B2 | Treatment of pain and/or pain related symptoms associated with dysmenorrhea | Alyra Biotech Pty Ltd (AU) | 2022-08-02 | — | — | US | claimed |
| EP-3999110-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114432285-A | Application of Resatorvid in up-regulating EFTUD2 expression and inhibiting HBV (hepatitis B virus) drugs | 江苏省人民医院（南京医科大学第一附属医院） | 2022-05-06 | — | — | CN | claimed |
| CN-114404593-A | Medicine for treating pituitary adenoma, preparation method and application thereof | 武汉叶风生物科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | claimed |
| WO-2022066825-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-03-31 | — | — | WO | claimed |
| EP-2528598-B1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | TAKEDA PHARMACEUTICAL (JP) | 2016-01-13 | — | — | EP | claimed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | claimed |
| WO-2011093512-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | WO | claimed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594278-B2 | Method for treatment of muscular dystrophy | MTPN, FAP, CPT1B | TLR4 3052/4885MRGPRX1 3437/4885TSPO 3812/4885 |
| US-20260034087-A1 | COMPOSITION COMPRISING A TLR4/MD2 PATHWAY INHIBITOR AND AN EGFR INHIBITOR AND ITS USE IN CANCER TREATMENT | TLR4, MYD88, TLR2 | TLR4 1/4885MRGPRX1 1663/4885TSPO 4282/4885 |
| US-20250375534-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | TLR3, TLR9, SARNP | TLR4 207/4885MRGPRX1 602/4885TSPO 1062/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | TLR4 3/4885MRGPRX1 179/4885TSPO 2339/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | TLR4 13/4885MRGPRX1 275/4885TSPO 1990/4885 |
| US-20250262192-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | TGFB1, TGFB2, SMAD3 | TLR4 43/4885MRGPRX1 2132/4885TSPO 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.